08:00 , Nov 19, 2012 |  BC Week In Review  |  Clinical News

Allist Pharmaceuticals, Prometic preclinical data

In rat model of kidney fibrosis, PBI-4419 inhibited connective tissue growth factor (CTGF) and collagen I mRNA expression. PBI-4419 is an orally active third-generation analog of PBI-1402, which is a chemoprotective activator of...
07:00 , Nov 1, 2010 |  BC Week In Review  |  Company News

Allist Pharmaceuticals, Prometic deal

Allist received exclusive rights to develop and commercialize ProMetic's PBI-1402 to treat chemotherapy-induced anemia (CIA) and cancer-related anemia and PBI-4419 to treat fibrotic diseases in China. Allist will fund all development required for...